Log in to save to my catalogue

Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled tria...

Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled tria...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1751201955

Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial

Publication information

Publisher

England: Elsevier Ltd

More information

Scope and Contents

Contents

Summary Background Multicentric Castleman's disease is a rare lymphoproliferative disorder driven by dysregulated production of interleukin 6. No randomised trials have been done to establish the best treatment for the disease. We assessed the safety and efficacy of siltuximab—a chimeric monoclonal antibody against interleukin 6—in HIV-negative pat...

Alternative Titles

Full title

Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_1751201955

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1751201955

Other Identifiers

ISSN

1470-2045

E-ISSN

1474-5488

DOI

10.1016/S1470-2045(14)70319-5

How to access this item